176 related articles for article (PubMed ID: 16154489)
1. Patterns of care, outcomes, and direct health plan costs of antiepileptic therapy: a pharmacoeconomic analysis of the available carbamazepine formulations.
Garnett WR; Gilbert TD; O'Connor P
Clin Ther; 2005 Jul; 27(7):1092-103. PubMed ID: 16154489
[TBL] [Abstract][Full Text] [Related]
2. A naturalistic comparison of amoxicillin/clavulanate extended release versus immediate release in the treatment of acute bacterial sinusitis in adults: A retrospective data analysis.
Jackson J; Fernandes AW; Nelson W
Clin Ther; 2006 Sep; 28(9):1462-71. PubMed ID: 17062318
[TBL] [Abstract][Full Text] [Related]
3. Improved CNS tolerability following conversion from immediate- to extended-release carbamazepine.
Miller AD; Krauss GL; Hamzeh FM
Acta Neurol Scand; 2004 Jun; 109(6):374-7. PubMed ID: 15147458
[TBL] [Abstract][Full Text] [Related]
4. Carbamazepine extended-release capsules use in bipolar disorder: efficacy and safety in adult patients.
Ginsberg LD
Ann Clin Psychiatry; 2006; 18 Suppl 1():9-14. PubMed ID: 16754406
[TBL] [Abstract][Full Text] [Related]
5. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
6. Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
Konsil J; Dechasathian S; Mason DH; Stevens RE
J Pharm Pharm Sci; 2002; 5(2):169-75. PubMed ID: 12207869
[TBL] [Abstract][Full Text] [Related]
7. Adverse event load in bipolar participants receiving either carbamazepine immediate-release or extended-release capsules: a blinded, randomized study.
El-Mallakh RS; Salem MR; Chopra AS; Mickus GJ; Penagaluri P
Int Clin Psychopharmacol; 2009 May; 24(3):145-9. PubMed ID: 19367153
[TBL] [Abstract][Full Text] [Related]
8. Effects of antiepileptic drug substitutions on epileptic events requiring acute care.
Rascati KL; Richards KM; Johnsrud MT; Mann TA
Pharmacotherapy; 2009 Jul; 29(7):769-74. PubMed ID: 19558250
[TBL] [Abstract][Full Text] [Related]
9. Safety of carbamazepine extended-release capsules in bipolar disorder polypharmacy.
Ginsberg LD
Ann Clin Psychiatry; 2006; 18 Suppl 1():19-22. PubMed ID: 16754408
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data.
Locklear JC; Alemayehu B; Brody RS; Chavoshi S; Tunceli O; Kern D; Earley WR
Clin Ther; 2013 Dec; 35(12):1923-32. PubMed ID: 24275622
[TBL] [Abstract][Full Text] [Related]
11. Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: an analysis of third-party managed care claims data.
Lee WC; Balu S; Cobden D; Joshi AV; Pashos CL
Clin Ther; 2006 Oct; 28(10):1712-25; discussion 1710-1. PubMed ID: 17157128
[TBL] [Abstract][Full Text] [Related]
12. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population.
Davis KL; Candrilli SD; Edin HM
Epilepsia; 2008 Mar; 49(3):446-54. PubMed ID: 18031549
[TBL] [Abstract][Full Text] [Related]
15. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy.
Powell G; Saunders M; Marson AG
Cochrane Database Syst Rev; 2010 Jan; (1):CD007124. PubMed ID: 20091617
[TBL] [Abstract][Full Text] [Related]
16. [The clinical and economic impact of generic drugs in the treatment of epilepsy].
Argumosa A; Herranz JL
Rev Neurol; 2005 Jul 1-15; 41(1):45-9. PubMed ID: 15999330
[TBL] [Abstract][Full Text] [Related]
17. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine.
Ficker DM; Privitera M; Krauss G; Kanner A; Moore JL; Glauser T
Neurology; 2005 Aug; 65(4):593-5. PubMed ID: 16116122
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage.
Bondareva IB; Jelliffe RW; Gusev EI; Guekht AB; Melikyan EG; Belousov YB
J Clin Pharm Ther; 2006 Jun; 31(3):211-21. PubMed ID: 16789986
[TBL] [Abstract][Full Text] [Related]
19. Resource use and cost implications of switching among warfarin formulations in atrial fibrillation patients.
Kwong WJ; Kamat S; Fang C
Ann Pharmacother; 2012 Dec; 46(12):1609-16. PubMed ID: 23150608
[TBL] [Abstract][Full Text] [Related]
20. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study.
Blonde L; Dailey GE; Jabbour SA; Reasner CA; Mills DJ
Curr Med Res Opin; 2004 Apr; 20(4):565-72. PubMed ID: 15119994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
